Open AccessLevel of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and therapy effectiveness in triple-negative breast cancer
Author(s) -
А. Ф. Насретдинов,
Н. И. Султанбаева,
Ш. И. Мусин,
А. В. Пушкарев,
К. V. Menshikov,
В. А. Пушкарев,
А. В. Султанбаев
Publication year - 2020
Publication title -
opuholi ženskoj reproduktivnoj sistemy
Language(s) - English
Resource type - Journals
eISSN - 1999-8627
pISSN - 1994-4098
DOI - 10.17650/1994-4098-2020-16-1-65-70
Subject(s) - triple negative breast cancer , breast cancer , biomarker , oncology , cancer , immunohistochemistry , cancer research , medicine , biology , genetics
In breast cancer, genetic profile and expression of immunohistochemical markers determine prognosis and treatment scheme. Triple-negative breast cancer is characterized by absence of hormone receptor expression and negative HER2 status, as well as high proliferative index. These features of the tumor tissue limit doctors» selection of antitumor drugs. Development of triple-negative variant of tumor tissue is associated with a mutation in the BRCA1/2 gene. Consequently, determination of BRCA1/2 mutations is a prognostic biomarker, and in triple-negative cancer presence of expression of immune checkpoint proteins, multiprotein receptors on the surface of immune cells and tumor tissue play an important role in prognosis and selection of treatment strategy. Additionally, some studies demonstrate existence of multiple prognostic markers which allow to divide patients with triple-negative breast cancer into subgroups facilitating prognosis and selection of treatment strategy.